Enliven Therapeutics, Inc. announced that it has entered into a securities purchase agreement to issue 5,357,144 shares at a price of $14 per share for the gross proceeds of $75,000,016 and pre funded warrants at a price of $13.999 per warrant for the total gross proceeds of $90,000,000 on March 19, 2024. The Pre-Funded Warrants will be exercisable into 1,071,505 shares and will have an exercise price of $0.001 per share of common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.47 USD | -1.69% | +4.89% | +55.13% |
24/06 | Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to S&P Pharmaceuticals Select Industry Index | CI |
11/06 | Baird Initiates Enliven Therapeutics With Outperform Rating, $32 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.13% | 1.01B | |
+16.45% | 122B | |
+21.96% | 116B | |
+25.36% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-15.75% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding